São Paulo, July 3, 2024 – Eurofarma, a Brazilian-owned pharmaceutical multinational operating in 22 countries and the largest investor in innovation in Brazil, has just joined the Digital Therapeutics Alliance (DTA), a non-profit organization with the vision of advancing the development of digital therapeutic solutions to support the transformation of the global healthcare system. The company is the first pharmaceutical multinational in Latin America to make this membership move.

“This is an important step for us, as it brings us closer to the world’s leading digital therapy companies, enabling us to identify partnership and business opportunities that benefit patients in Latin America,” says Érica de Menezes, manager of EurON Ventures, Eurofarma’s corporate venture arm responsible for investments in startups.

Founded in 2017, the DTA brings together global pharmaceutical industries, healthtechs, healthcare providers, and other healthcare organizations to refine the understanding of digital therapy and guide the development, regulatory approval, and commercialization of innovations.

This purpose aligns with Eurofarma, particularly with the company’s Digital Health division, which is part of the EurON platform. In 2023, the company introduced Scrolling Therapy to the market, an innovative and experimental facial expression recognition initiative powered by artificial intelligence, which allows patients with Parkinson’s disease to interact on social media using facial expressions. “This was our first official delivery of a digital solution. With DTA membership, we aim to accelerate the launch of complementary alternatives for patients across various healthcare fields,” adds Pereira.

Innovative DNA

Innovation has been part of Eurofarma’s dynamics for many years, which is why it is the Brazilian pharmaceutical company that invests the most in this area, making it one of its pillars for sustainable growth. In 2023 alone, more than R$ 680 million was directed toward innovation projects, including digital initiatives and startups, as well as Research & Development.

Also in 2023, Eurofarma launched EurON, created to unify the company’s digital transformation under a single, strong brand capable of conveying all initiatives synergistically. Alongside the Digital Health division, the brand also encompasses Data, Open Innovation, Six Sigma, and Corporate Venture areas. To learn more, visit euroneurofarma.com.

About Eurofarma

Founded in 1972, Eurofarma operates in the healthcare sector, producing and marketing products and services to improve people’s quality of life. With a focus on generating shared value, it covers major pharmaceutical segments such as prescription drugs, OTC and personal care, generics, hospital, oncology, and animal health, as well as offering third-party manufacturing services. With broad therapeutic class coverage, the portfolio includes over 2,000 products and 3,700 SKUs, serving major medical specialties.

A leader in prescription drugs in Latin America and Brazil, where it holds the second position in generics, Eurofarma is present in 22 countries, with 100% coverage in Latin America and operations in the U.S. and Africa. It has 12,600 employees and 11 factories, producing a total of 573 million units in 2023. That same year, it invested over R$ 680 million in innovation and achieved total net revenue of R$ 9.1 billion. Over the last 15 years, Eurofarma has recorded an average annual growth of 17%.

Eurofarma on Social Media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma | YouTube: @eurofarmalab